2024
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-grade
2022
PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist
Belzer A, Bhullar S, Leventhal J. PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports 2022, 11: 158-167. DOI: 10.1007/s13671-022-00365-6.Peer-Reviewed Original ResearchDermatologic adverse eventsBody surface areaClinical trialsAdverse eventsCommon dermatologic adverse eventsMucositis/stomatitisFrequent adverse eventsAddition of prednisoneMajority of malignanciesPI3K inhibitorsMaculopapular rashProphylactic therapyPsoriasiform eruptionTopical corticosteroidsSun avoidanceSummaryThis reviewPI3KiK inhibitorsInpatient DermatologistTrialsCancer therapyRashTherapyDermatologistsOverview of diagnostics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply